Follicular Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

What is follicular lymphoma, what are the symptoms of Nicola Mendelsohn's blood cancer and what's the life expectancy? - The Sun



The Sun
 
What is follicular lymphoma, what are the symptoms of Nicola Mendelsohn's blood cancer and what's the life expectancy? 
The Sun
It's a type of blood cancer, and Facebook boss Nicola Mendelsohn has opened up about her diagnosis, but what exactly is follicular lymphoma? By Anna Johnstone. 5th February 2018, 9:34 am. Updated: 5th February 2018, 9:34 am. AROUND 1,900 people are ...
What is silent cancer follicular lymphoma, and how do you know if you have it? Telegraph.co.uk
'I Want to Use My Voice to Help:' Facebook Exec Reveals Incurable Cancer Fortune
Facebook boss reveals she has incurable cancer The Independent
BBC News  -Daily Mail 
all 21 news articles » 


Imbruvica Only Moderately Effective in Relapsed Follicular Lymphoma Patients, Phase 2 Trial Shows - Lymphoma News Today



Lymphoma News Today
 
Imbruvica Only Moderately Effective in Relapsed Follicular Lymphoma Patients, Phase 2 Trial Shows 
Lymphoma News Today
It is an oral therapy approved for treatment of many B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia. Imbruvica was also recently approved for the treatment of chronic graft-versus ...

 


Chemo/Radioimmunotherapy Treatment Strategy Induces 90% PFS at 3 Years in Follicular Lymphoma - Targeted Oncology



Targeted Oncology
 
Chemo/Radioimmunotherapy Treatment Strategy Induces 90% PFS at 3 Years in Follicular Lymphoma 
Targeted Oncology
Patients had stage III, IV, or bulky stage II follicular lymphoma, grades 1, 2, or 3a. The median age among enrolled patients was 52 (range, 46-60) and 52% were female. The majority (62%) of patients had an ECOG performance status of 0. Twenty-four ...

 


FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma - OncLive



OncLive
 
FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma 
OncLive
A new drug application has been submitted to the FDA for duvelisib for a full approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval in relapsed/refractory follicular lymphoma.
Verastem takes AbbVie's blood cancer castoff to the FDA ... Endpoints News
Xconomy: At Verastem, Infinity's Former Blood Cancer Drug Heads ... Xconomy
Verastem submits U.S. marketing application for lead candidate ... Seeking Alpha

all 5 news articles » 


CHOP-RIT Regimen Improves PFS Over R-CHOP in Follicular ... - Targeted Oncology



Targeted Oncology
 
CHOP-RIT Regimen Improves PFS Over R-CHOP in Follicular ... 
Targeted Oncology
Progression-free survival (PFS) was improved by nearly 15% with CHOP-RIT compared with R-CHOP alone in previously untreated patients with follicular lymphoma (FL), according to findings from the phase III SWOG-S0016 trial published in the Journal of ...
Follicular Lymphoma Patients Seen to Benefit from Aggressive ... Lymphoma News Today

all 2 news articles » 


Immunotherapy in the Treatment of Follicular Lymphoma - OncLive - OncLive



OncLive
 
Immunotherapy in the Treatment of Follicular Lymphoma - OncLive 
OncLive
Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.

and more » 


Follicular Lymphoma: Novel Approaches With Rituximab - OncLive - OncLive



OncLive
 
Follicular Lymphoma: Novel Approaches With Rituximab - OncLive 
OncLive
Ian W. Flinn, MD, PhD; Loretta J. Nastoupil, MD; Peter Martin, MD, MS; Grzegorz S. Nowakowski, MD; and Anas Younes, MD, elucidate the potential value of the R-squared regimen and rituximab biosimilars as part of the treatment landscape for follicular ...

and more » 


FDA Approval in Prostate Cancer, NDA Submitted in CLL and ... - OncLive



OncLive
 
FDA Approval in Prostate Cancer, NDA Submitted in CLL and ... 
OncLive
Gina Columbus reports on an FDA approval in prostate cancer, a new drug application submitted in CLL and follicular lymphoma, a clinical hold placed on trials of BPX-501, and promising findings in studies of melanoma, non-small cell lung cancer, and ...

and more » 


Immunochemotherapy Remains Standard for High-Risk Follicular Lymphoma - Cancer Network



Immunochemotherapy Remains Standard for High-Risk Follicular Lymphoma 
Cancer Network
But the estimated 10-year cumulative incidence of death from myelodysplastic syndrome or acute myeloid leukemia was significantly higher for patients in the CHOP-RIT arm compared with the R-CHOP arm (4% vs 0.9%; P = .02), despite the small number of ...

 


Investigational Rituximab Biosimilar Matches Response Rate in Follicular Lymphoma - Cancer Network



Investigational Rituximab Biosimilar Matches Response Rate in Follicular Lymphoma 
Cancer Network
?These results reinforce the potential of our proposed rituximab biosimilar in providing a safe and effective treatment option for patients.? The phase III REFLECTIONS B3281006 trial was a double-blind phase III study that compared the safety and ...